StemCell Therapy

LabXchange by Amgen Foundation and Harvard's Faculty of Arts and Sciences Reimagines the Science Experience for Students around the Globe

Purpose-Built to Address Educational Barriers With Personalized Instruction

Virtual Lab Simulations Help Students Develop the Science Skills Needed to Solve Tomorrow's Challenges

THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Jan. 22, 2020 /PRNewswire/ --The Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS)today announced the global launch of LabXchange, a free online science education platform that provides users with access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. LabXchange is purpose-built to drive more inclusion in the scientific process and spark collaboration to build creative, team-based approaches to real-world problems.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8490258-amgen-foundation-harvard-labxchange/

"Too many high school and college students lack the opportunity to directly explore the scientific process where you build a hypothesis, understand a method, and determine how to apply it to an appropriate experimental problem," said Robert Lue, Ph.D., principal investigator of LabXchange and professor of the Practice of Molecular and Cellular Biology at Harvard. "For many students, science can feel like a collection of facts to memorize which is contrary to what the scientific process is it's a journey that requires bold thinking and deep imagination. With LabXchange, more students can come together and experience the joy of discovery."

Featuring virtual lab experiments developed at LabXchange along with other world-class assets created by validated partners, LabXchange brings the scientific process to life. By simulating key techniques in molecular and cellular biology, like using CRISPR to correct genetic defects, students can explore a wide range of scientific methods and build their acumen in harnessing science to solve real-life problems.

"Everyone needs science, and science needs everyone," said Robert A. Bradway, chairman and chief executive officer at Amgen. "At a time of remarkable scientific progress, we're excited by the potential of LabXchange to educate and inspire both students and lifelong learners of all ages."

LabXchange is designed to level the playing field for students and to promote science literacy for all. Key features of LabXchange include:

LabXchange builds upon other Amgen Foundation programs that support science education, such as the Amgen Biotech Experience and Amgen Scholars that are also at Harvard FAS and institutions around the world. To date, the Foundation has contributed more than $150 million to advancing science education programming globally as part of its mission to facilitate global collaboration on the United Nations Sustainable Development Goals (SDGs), notably SDG #4 on Quality Education, but also SDG #3 on Good Health and Well-Being.

For more information, please visit http://www.LabXchange.org, and engage with us via @LabXchange on Twitter using #ScienceMadePossible.

About the Amgen Foundation The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated over $300 million to local, regional, and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars and the Amgen Biotech Experience. For more information, visit AmgenInspires.com and follow us on Twitter @AmgenFoundation.

About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980,Amgenhas grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Story continues

For more information, visitwww.amgen.comand follow us onTwitter @Amgen.

About the Faculty of Arts and Sciences at Harvard University The Faculty of Arts and Sciences is the largest of the seven faculties that constitute Harvard University and is the only division of the university responsible for both undergraduate and graduate education. FAS advances knowledge, improves learning, and shapes leaders.

For more information, visit http://www.fas.harvard.edu/

CONTACT: Amgen, Thousand OaksJessica Akopyan, 805-447-0974(Media) TrishHawkins, 805-447-5631 (Media)

Harvard Faculty of Arts and Sciences, CambridgeRachael Dane, 617-456-0106 (Media)

With LabXchange's interactive lab experiments, students have access to one of the most central aspects of being a scientist: working in a laboratory.

LabXchange gives students access to a library of world-class educational videos, interactive simulations and personalized instruction to aid them in their scientific discovery.

Every student deserves an equal opportunity to prepare for and be successful in science, regardless of income, race gender or geography. LabXchange ensures this opportunity by providing students access to free online science education and inspiring lifelong learning.

LabXchange brings the experience of working and learning science in a lab straight to students. Through virtual lab experiments, high-quality videos and online collaboration with others in the global science community, students can experience the scientific process for themselves.

View original content:http://www.prnewswire.com/news-releases/free-labxchange-science-education-accelerator-launched-by-amgen-foundation-and-harvards-faculty-of-arts-and-sciences-300990930.html

SOURCE Amgen

See more here:
Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences - Yahoo Finance

This unique report provides UK sales and market share estimates for major suppliers of molecular diagnostic products. The report also presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in RandD, collaborative arrangements, and business strategies.

New York, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "2020 U.K. Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies" - https://www.reportlinker.com/p05838907/?utm_source=GNW

Competitive Assessments

- Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca Biopharma - Beckman Coulter/Danaher - Becton Dickinson - Biokit - bioMerieux - Bio-Rad - Biotest - Cepheid - Decode Genetics - Diadexus - Eiken Chemical - Elitech Group - Enzo Biochem - Exact Sciences - Fujirebio - Grifols - Hologic - Illumina - LabCorp - Leica Biosystems - Li-Cor Biosciences - Myriad Genetics - Ortho-Clinical Diagnostics - PerkinElmer - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - Shimadzu - Siemens Healthineers - Sierra Molecular - Takara Bio - Tecan Group - Thermo Fisher

List of Tables

UK Molecular Diagnostics Market by Major Supplier UK HIV/Hepatitis NAT Market Reagent Sales by Major Supplier

Contains 121 pages and 2 tables

Read the full report: https://www.reportlinker.com/p05838907/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

More:
2020 U.K. Molecular Diagnostics Market: Sales and Market Shares of Major Suppliers, and Profiles of Current and Emerging Companies - Yahoo Finance

There is an entire cinematic subculture devoted to sharks that find ingenious ways to travel on land, be it via sharknado, genetic hybridization, or occult forces. Meanwhile, in the real world, there actually is a family of sharks that have evolved to walk on land, though they are much smaller, cuter, and less ravenous for human flesh than their counterparts on film.

These walking sharks belong to the Hemiscyllium family, which is the newest lineage of sharks on Earth, according to a study published on Monday in the journal Marine and Freshwater Research. Using specially adapted fins, the sharks are able to pull themselves across reefs in their tropical Indo-Australian habitat, even when they are not submerged by water.

Theyre incredibly cute little animals and are really more like a gecko walking around than a shark, said co-author Mark Erdmann, a coral reef ecologist at the California Academy of Sciences, in a call.

They are not big swimmers, added Erdmann, who also serves as vice president of the Asia-Pacific Field Division of Conservation International, an American nonprofit environmental organization. They stay on the same reef where they are born. They are very much homebodies.

While these ambulatory skills have been documented in previous studies, Erdmann and his colleagues shed new light on the familys evolutionary origins by analyzing DNA from the nine currently recognized species of Hemiscyllium. The team conducted a molecular phylogenetic analysis of the sharks, which means they used DNA sequencing to figure out the sharks genetic relationships to each other, and the wider shark lineage.

The results revealed that walking sharks are the youngest branch of the shark family tree, which dates back about 450 million years.

With our molecular clock, weve been able to show that this group really only branched off from their nearest ancestor about nine million years ago and theyve been actively radiating ever since, Erdmann said. Obviously in human terms, that still seems like a long time ago, but for sharks, and for speciation in general, thats actually very recent.

This timeline of speciation coincides with major geological changes that were occurring as the Australian continental plate slammed into landforms north of it. These tectonic processes, accompanied by volcanic eruptions, have repeatedly scrambled the region over millions of years like a giant island disco, as Erdmann described it.

Walking sharks weathered these geological storms by flourishing in newly created shallow reefs, where they gained the ability to wriggle overland to remote tidal pools. The sharks, which typically measure a foot or two in length, have also adapted to endure the oxygen depletion that occurs in these isolated pools at low tide.

But despite these amazing adaptations, walking sharks are vulnerable to natural disasters, such as tsunamis and volcanic eruptions. The fact that they have such tiny little distributionseach one has a small pocket like a bay or an archipelagomakes them just intrinsically susceptible to large perturbations and extinction events, Erdmann said.

The sharks are also increasingly facing anthropogenic pressures, including rising popularity as an aquarium attraction and potential habitat loss due to coastal development. For that reason, conservationists have been working to secure more protections for walking sharks, and have succeeded in adding three of the nine species to the International Union for Conservation of Nature Red List.

Erdmann and his colleagues plan to conduct many more expeditions to the Indo-Pacific reefs where these animals thrive, in order to learn more about their conservation requirements and the extent of their range and varieties.

The genetics very much confirm that these are a very young radiation and they seem to still be actively speciating, so we reckon that theres probably a good chance of a few more species of walking shark out there, he said. This shows to us that they very much are still an active part of our evolving planet, and thats really good news.

Read the original:
Walking Sharks Are the Newest Branch of the Shark Family Tree - VICE

CHICAGO, Jan. 20, 2020 /PRNewswire/ -- According to the new market research report "Gene Therapy Marketby Vectors [Non-viral (Oligonucleotides), Viral (Retroviral (Gammaretroviral, Lentiviral), Adeno-associated], Indication (Cancer, Neurological Diseases), Delivery Method (In Vivo, Ex Vivo), Region - Global Forecast to 2024", published by MarketsandMarkets, is projected to reach USD 13.0 billion by 2024 from USD 3.8 billion in 2019, at a CAGR of 27.8% from 2019 to 2024.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122857962

The high incidence of cancer and other target diseases, availability of reimbursement, and the launch of new products are the major factors driving the growth of the market.

The non-viral vectors segment accounted for the largest share of the market, by vector, in 2018

The Gene Therapy Market, by vector, has been segmented into viral and non-viral vectors. Non-viral vectors accounted for the largest share of the market in 2018. This is mainly attributed to the high market penetration of oligonucleotide-based non-viral vector gene therapies.

Browsein-depth TOC on "Gene Therapy Market" 127 - Tables25 - Figures 129 - Pages

The demand for gene therapies for the treatment of cancer is expected to grow at a high rate

Based on indication, the market is segmented into neurological diseases, cancer, hepatological diseases, Duchenne muscular dystrophy, and other indications. The neurological diseases segment accounted for the largest share of the market in 2018. However, the cancer segment is estimated to grow at the highest CAGR during the forecast period owing to the increasing incidence of cancer and the rising demand for CAR T-cell therapies.

Get 10% Customization Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=122857962

North America is the largest regional market for gene therapy products

The global Gene Therapy Market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the market, followed by Europe. Moreover, the North American market is estimated to register the highest growth rate during the forecast period. Factors such as the rising prevalence of chronic diseases, high healthcare expenditure, presence of advanced healthcare infrastructure, favorable reimbursement scenario, and the presence of major market players in the region are driving market growth in North America.

The prominent players operating in the Gene Therapy Market include Biogen (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Novartis AG (Switzerland), Amgen, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Itlay), Orchard Therapeutics plc. (UK), Sibiono GeneTech Co. Ltd. (China), Alnylam Pharmaceuticals, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Dynavax Technologies (US), Jazz Pharmaceuticals, Inc. (Ireland), and Akcea Therapeutics (US).

Browse Adjacent Markets @Biotechnology MarketResearch Reports & Consulting

Get Special Pricing on Bundle Reports:https://www.marketsandmarkets.com/RequestBundleReport.asp?id=122857962

Browse Related Reports:

Regenerative Medicine Marketby Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024

Viral Vector Manufacturing Marketby Type (Retrovirus, Gammaretrovirus, AAV), Disease (Cancer, Infectious Disease, Genetic Disorders), Application (Gene Therapy, Vaccinology), End User (Biotech companies, Research Institutes) - Global Forecast to 2023

About MarketsandMarkets:

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Shelly SinghMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA : +1-888-600-6441Email: sales@marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/gene-therapy.asp Research Insight:https://www.marketsandmarkets.com/ResearchInsight/gene-therapy-market.asp Visit Our Website:https://www.marketsandmarkets.com

Logo:https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

Read more:
Gene Therapy Market Worth $13.0 Billion by 2024 - Exclusive Report by MarketsandMarkets - PR Newswire UK

We, Global Marketers.biz, after comprehensive analysis, have introduced a new research study on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market. The report provides a unique competitive analysis of the size, segmentation, competition, trends, and outlook in the manufacturers operating in the industry. It covers the key manufacturers profiles in detail along with market entry strategies, production analysis, market share, revenue forecast and regional analysis of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry. It particularly delivers wide-ranging analytical information on regional segmentation.

Download Free Sample PDF Report Inquire Before Buying

The researchers team presents the analytical data and figures in the report in an effectual way with the help of graphs, diagrams, pie charts, and other pictorial illustrations. The report focuses on providing the clients and other readers with all the necessary information regarding Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market share, new product launch, applications, provinces, businesses, economic growth, and supply and demand rate. It examines the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry potentials for each geographical region with respect to the client purchasing patterns, macroeconomic parameters, market demand and supply states, and evolution rate.

This study considers the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market value and volume generated from the sales of the following segments:

Growth Drivers and Industry Trends:

The Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market is divided into different segments with reference to the geographic, types, applications, and manufacturers. Our team of scholars has followed a focused and realistic research outline in order to inspect the vital market dynamics like drivers, restraints, and opportunities in many areas across the world.

Regional Analysis:

The report covers a forecast and an exploration of the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market on a global and regional level. The historical data is given from 2015-2020 and the forecast period is from 2020-2026 based on revenue (USD Billion). The Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry was estimated at XX Million US$ in 2020 and is probable to grasp XX Million US$ by 2026, at a CAGR of XX% throughout 2020-2026.

Key Focused Regions in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market:

Table of Content

1 Global Market Overview

1.1 Scope of Data

1.1.1 Scope of Yields

1.1.2 Scope of Companies

1.1.3 Scope of End-Use

1.1.4 Scope of Product Type

1.1.5 Scope of Geographies

1.2 Global Market Size

2 Regional Market

2.1 Regional Sales

2.2 Regional Demand

2.3 Regional Trade

3 Key Manufacturers

3.1 Company A

3.1.1 Company Info

3.1.2 Product & Services,

3.1.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.1.4 Recent Expansion

3.2 Company B

3.2.1 Company Info

3.2.2 Product & Services

3.2.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.2.4 Recent Expansion

3.3 Company C

3.3.1 Company Info

3.3.2 Product & Services

3.3.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.3.4 Recent Expansion

3.4 Company D

3.4.1 Company Info

3.4.2 Product & Services

3.4.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.4.4 Recent Expansion

3.5 Company E

3.5.1 Company Info

3.5.2 Product & Services

3.5.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.5.4 Recent Expansion

3.6 Company F

3.6.1 Company Info

3.6.2 Product & Services

3.6.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.6.4 Recent Expansion

3.7 Company G

3.7.1 Company Info

3.7.2 Product & Services

3.7.3 Corporate Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

3.7.4 Recent Expansion

4 Major End-Use

5 Market by Type

6 Price Overview

6.1 Price by Manufacturers

6.2 Price by End-Use

6.3 Price by Type

7 Research Conclusions

8 Appendix

8.1 Methodology

8.2 Research Data Source

Customization of the Report: This report can be modified to meet the clients requirements. Please connect with our sales squad (inquiry@globalmarketers.biz), who will guarantee that you get a report that suits your necessities.

To know More Details About Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market research Report @: https://www.globalmarketers.biz/report/pharma-&-healthcare/global-stem-cell-and-platelet-rich-plasma-(prp)-alopecia-therapies-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/141736 #table_of_contents

See the original post:
Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market By Trends, Analysis and Forecast to 2025. - Expedition 99

In 2018, the market size of HbA1c Analyzers Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for HbA1c Analyzers .

This report studies the global market size of HbA1c Analyzers , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Request Sample Report @https://www.mrrse.com/sample/19996?source=atm

This study presents the HbA1c Analyzers Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. HbA1c Analyzers history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global HbA1c Analyzers market, the following companies are covered:

competitive landscape. The research report profiles key players of the HbA1c analyzers market, along with their strategies, products, and financials.

HbA1c Analyzers Market Segmentation

In order to present the impact of the crucial aspects, our analysts have formed key segments of the HbA1c analyzers market. The market has been segmented based on the product type, technology, modality, end user, and region. The report studies these segments in detail and offers reliable statistics and data regarding the growth of the HbA1c analyzers market.

Product Type

Technology

Modality

End User

Region

Equipment

Ion Exchange Chromatography

Portable HbA1c Analyzers

Hospitals

North America

Reagents & Consumables

Boronate Affinity HPLC

Benchtop HbA1c Analyzers

Diagnostic Centers

Latin America

HPLC

Academic and Research Institutes

Europe

Boronate Affinity Technology

South Asia

East Asia

Oceania

MEA

HbA1c Analyzers Market Key Questions Answered

The study on HbA1c analyzers market highlights distinguished and rare insight, in order to help the stakeholders gain exclusive information. Our analysts have answered numerous questions encircling the HbA1c analyzers market. Some of the questions answered in the report include:

HbA1c Analyzers Market Research Methodology

A systematic approach has been followed to draw crucial insights into the HbA1c analyzers market. Analysts at PMR follow a top-bottom and bottom-top approach to assess the HbA1c analyzers market and validate the information obtained from the primary as well as the secondary research methodology. In order to conduct primary research, interviews with a number of technology developers, distributors, manufacturers, key opinion leaders, and market heads were conducted.

Through the primary research, information about the key drivers and restraints, opportunities, winning strategies, regional value split, anticipated growth projections, and market concentrations has been acquired. In order to carry out secondary research, analysts at PMR studied numerous sources using essential sources. Some of the secondary sources include company websites, company annual reports, White papers, and financial reports. The paid publications that were referred to include BVD, Morningstar, Meltwaters, Genios, GBI, and Factiva. Through secondary research, information about the market share by region, industry growth projections, key insights on market segments, trends, and opportunities, can be obtained.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/19996?source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe HbA1c Analyzers product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of HbA1c Analyzers , with price, sales, revenue and global market share of HbA1c Analyzers in 2017 and 2018.

Chapter 3, the HbA1c Analyzers competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the HbA1c Analyzers breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

Buy This Report @ https://www.mrrse.com/checkout/19996?source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, HbA1c Analyzers market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe HbA1c Analyzers sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Originally posted here:
Personalized Medicine Market to Surge at a Robust Pace in Terms of Revenue Over 2016 2026 - Fusion Science Academy

The Global Cord Blood Stem Cell Market Research Report presents comprehensive information linked to the market. The updated market report assists clients to analyze better and predicts the Cord Blood Stem Cell market growth pattern at the global as well as regional level. Cord Blood Stem Cell Market 2020-2029 covers market characteristics, size, and growth, segmentation, regional divisions, Cord Blood Stem Cell competitive landscape, market shares, trends and plans for this market. Cord Blood Stem Cell market report provides an analysis of Cord Blood Stem Cell industry on the basis of popular market trends, types, top Organizations and variety of applications.

For better understanding, the Cord Blood Stem Cell Market study is organized in a chapter-wise manner.[Click To Get Detailed Table Of Contents]The report helps to See who are top Cord Blood Stem Cell key players, what benefits they Expect? Define the Key strength and success factor of Cord Blood Stem Cell. The worldwide Cord Blood Stem Cell industry also delivers the current market scenario based on report status, market maturity as well as the Cord Blood Stem Cell past and upcoming market trends which will boost the development of the Cord Blood Stem Cell industry. Additionally, the global market study provides essential industry frameworks along with key development methods and policies. The company divested its Cord Blood Stem Cell last year, which also impacted the Y-O-Y growth situations from 2020 to 2029.

For Better Understanding, Download Free Sample PDF Cord Blood Stem Cell Market Research Report @https://marketresearch.biz/report/cord-blood-stem-cells-market/request-sample

The detailed research report on Cord Blood Stem Cell Market gives an overview of the best players contributing to the industrial market and gives a wholly comprehensive look over the new records in the market. The primary vital manufacturers included in this report are Cord Blood Registry Systems Inc, Viacord Inc., China Cord Blood Corporation., Cord Blood America Inc, Cryo-Cell International Inc, Cryo-Save AG., Cordlife Group Ltd., Vita 34 AG., Lifecell International Pvt. Ltd., Stemcyte Inc.. This report begins with a market perspective and gives markets significant investment and the description of the worldwide Cord Blood Stem Cell market. The summary part of the report consists of Cord Blood Stem Cell market dynamics which covers market growth drivers, controlling elements, occasions and Cord Blood Stem Cell current trends together with the preference chain analysis and pricing detail study.

The report examines competition, product portfolios, and recent developments on the future Cord Blood Stem Cell Market.

Segmentation Covering:

Cord blood stem cell market segmentation by storage service:

Public cord blood bankPrivate cord blood bankCord blood stem cell market segmentation by application:

Blood diseaseCancerAcute leukaemiaKrabbe diseasesOther diseases

Regions Covering:

North America: US, Canada

Latin America: Brazil, Mexico, Rest of Latin America

Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe

Asia Pacific: China, India, Japan, Australia, South Korea, Rest of Asia Pacific

The Middle East and Africa: GCC, South Africa, Rest of Middle East and Africa

Inquire/Speak To Expert for Further Detailed Information About Cord Blood Stem Cell Report:https://marketresearch.biz/report/cord-blood-stem-cells-market/#inquiry

The research objectives of the Cord Blood Stem Cell Market are :

Analysis of Cord Blood Stem Cell market(Historical Data, Current, and Forecast) to analyze ratio of growth and Cord Blood Stem Cell market size.

Cord Blood Stem Cell Market risk, market opportunities, growth-driving forces, and confining factors of the business.

It provides a transparent research plan regarding the Cord Blood Stem Cell existing competitors together with rising ones.

New technologies and issues to investigate Cord Blood Stem Cell market dynamics.

Cord Blood Stem Cell Market Forecast 2020 to 2029.

Closely evaluate Cord Blood Stem Cell latest and developing market segments.

Cord Blood Stem Cell Market investigation with relevancy Cord Blood Stem Cell business value and volume.

Totally various strategies and approaches employed by competitors to reinforce growth in Cord Blood Stem Cell Market.

Finally, the research study provides a comprehensive view of the global Cord Blood Stem Cell market, offering market size and estimates for the period from 2020 to 2029.

Share Your Questions Here For More Details On this Report or Customizations As Per Your Need:https://marketresearch.biz/report/cord-blood-stem-cells-market/#request-for-customization

Contact Us

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

See original here:
Global Cord Blood Stem Cell Market Size 2020 | Key Players, Growth Insights, Demand Analysis and 2029 Forecast Research - News Monitoring

Coherent Market Insightscame with a new study titledGlobal Cell Banking Outsourcing Market Analysis 2012-2017 and Forecast 2020-2027which is an in-depth study and analysis of the market, shading light on many noteworthy points and trends. Our industry experts, with unique domain knowledge, have developed this report to offer analysis of Market Size, Share, Future Growth, and Opportunity. An inclusive and decision-making data in this report will be useful for your esteemed clients.Cell Banking Outsourcing MarketGrowth Analysis by Top Key Manufacturers that definitely Up your businessCharles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious Stedim Biotech Group)Ltd., BioReliance Corporation, BSL Bioservice Scientific Laboratories Munich GmbH, Cleancells, CordLife Group Ltd, Covance, Inc.

Download PDF with Recent all Updates & Trending Key Players with TOC: https://www.coherentmarketinsights.com/insight/request-pdf/1302

The study report validates the evaluation and volume of theCell Banking Outsourcing for the forthcoming years.Further it covers regions and country wise data that show a regional development status including market size, volume, value, and price. Then, the manufacturers data such as revenue, shipment, price, gross profit, interview record, and business distribution are also added. The aforementioned market is anticipated to reflect a positive growth trend between the years 2020 to 2027.

On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-

Cell Banking Outsourcing Market Taxonomy:

On the basis of type of bank:

On the basis of type of cell:

On the basis of phases of banking:

Ask more details or request custom reports to our experts at

The report then analyzes advancement and estimates development of the key players using the SWOT analysis. It also covers product categories, segments, competitive structure, new marketing plans, and collaborations. A detailed investigation on segments by market players, types, application, and geographical areas is also given in the report.

For competitor segment, the report includes global key players of Cell Banking Outsourcing as well as some small players. The details for each competitor include:

Main Business Information

SWOT Analysis

Sales, Revenue, Price and Gross Margin

Market Share

The market is controlled by these Renowned Players:

This report offers examination of the market in these districts covering, North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc.), Asia-Pacific (China, India, Japan, Southeast Asia etc.), South America (Brazil, Argentina etc.), Middle East & Africa (Saudi Arabia, South Africa etc.)with their crucial positions, size, production, consumption, revenue, and market share.

Download Exclusive Sample of this Premium Report at: https://www.coherentmarketinsights.com/insight/request-sample/1302

Market Segmented on the basis of Applications, size, product tye, technology amoung others.

Key Offerings of This Report:

Competitor Analysis Include:

Regional Market Analysis Market Analysis Market Overview 2012-2017 Local Supply, Import, Export, Local Consumption Analysis 2012-2017 Sales Price Analysis 2016 Market Share Analysis 2018-2023 Market Forecast, Growth, Opportunity

The report offers research conclusions, findingswhich can offer a summarized view of the Cell Banking Outsourcing. It then serves SWOT examination and venture return investigation, and other aspects such as the principle locale, economic situations with benefit, generation, demand, limit, supply, and market development rate and figure. The overall data was gathered by using many effective inquisitive tools like market attractiveness study, feasibility analyses, and predictable investment returns estimations.In short, the report encompasses all key entities regarding overall consequential study of the market.

Ask Questions to Expertise @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1302

About us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

Continue reading here:
Cell Banking Outsourcing Market Global Forecast to 2027 Charles River Laboratories, Cryo-Cell International Inc., BioOutsource (Part of Sartorious...

In this section:

Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Insulin, a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy. Sometimes your body doesnt make enoughor anyinsulin or doesnt use insulin well. Glucose then stays in your blood and doesnt reach your cells.

Over time, having too much glucose in your blood can cause health problems. Although diabetes has no cure, you can take steps to manage your diabetes and stay healthy.

Sometimes people call diabetes a touch of sugar or borderline diabetes. These terms suggest that someone doesnt really have diabetes or has a less serious case, but every case of diabetes is serious.

The most common types of diabetes are type 1, type 2, and gestational diabetes.

If you have type 1 diabetes, your body does not make insulin. Your immune system attacks and destroys the cells in your pancreas that make insulin. Type 1 diabetes is usually diagnosed in children and young adults, although it can appear at any age. People with type 1 diabetes need to take insulin every day to stay alive.

If you have type 2 diabetes, your body does not make or use insulin well. You can develop type 2 diabetes at any age, even during childhood. However, this type of diabetes occurs most often in middle-aged and older people. Type 2 is the most common type of diabetes.

Gestational diabetes develops in some women when they are pregnant. Most of the time, this type of diabetes goes away after the baby is born. However, if youve had gestational diabetes, you have a greater chance of developing type 2 diabetes later in life. Sometimes diabetes diagnosed during pregnancy is actually type 2 diabetes.

Less common types include monogenic diabetes, which is an inherited form of diabetes, and cystic fibrosis-related diabetes.

As of 2015, 30.3 million people in the United States, or 9.4 percent of the population, had diabetes. More than 1 in 4 of them didnt know they had the disease. Diabetes affects 1 in 4 people over the age of 65. About 90-95 percent of cases in adults are type 2 diabetes.1

You are more likely to develop type 2 diabetes if you are age 45 or older, have a family history of diabetes, or are overweight. Physical inactivity, race, and certain health problems such as high blood pressure also affect your chance of developing type 2 diabetes. You are also more likely to develop type 2 diabetes if you have prediabetes or had gestational diabetes when you were pregnant. Learn more about risk factors for type 2 diabetes.

Over time, high blood glucose leads to problems such as

You can take steps to lower your chances of developing these diabetes-related health problems.

[1] Centers for Disease Control and Prevention. National diabetes statistics report, 2017. Centers for Disease Control and Prevention website. http://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf (PDF, 1.3 MB) . Updated July, 18 2017. Accessed August 1, 2017.

See original here:
What is Diabetes? | NIDDK

NEW YORK, Jan. 21, 2020 /PRNewswire/ --

The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2019-2027.

Read the full report: https://www.reportlinker.com/p05774503/?utm_source=PRN

The market is driven by the factors such as, rising incidence of diabetes, growing geriatric population, increasing prevalence of obesity across the globe, and rapid technological advancement in diabetes care devices. However, the factors restraining the market growth are high cost of diabetes care devices and risks associated with the insulin delivery devices.Obesity, sedentary lifestyle and improper diet play a major role in increasing diabetes among the population worldwide.Physical activity is important to maintain the blood glucose level.

Lack of exercise and unhealthy diet such as diet high in fat and calories increase the risk for the development of obesity and diabetes.Obesity is one of the major problem and the biggest concern in all the communities across the globe.

Currently, more than one in two adults and nearly one in six children are obese.Obesity is one of the major issue affect people of all ages and incomes globally.

According to World Health Organization (WHO), in 2016, more than 1.9 billion adults aged 18 years and older were overweight. And out of these over 650 million adults were obese. Therefore, owing to these factors the market is likely to witness growth during the forecast period.Global diabetes care devices market was segmented by product and end user.The product segment was further divided as glucose monitoring devices and insulin delivery devices.

The glucose monitoring devices is further segmented into Glucometers, Lancets, Testing Strips and Other Glucose Monitoring Devices.The insulin delivery devices is further segmented into insulin pens, insulin syringes, insulin pumps and other insulin delivery devices.

The glucose monitoring devices is expected to dominate its market share in 2027 owing to the rise in the prevalence of the diabetes.Based on the end user the diabetes care device market is segmented into hospitals and clinics and home care.

The homecare held the major market share among the end user segment owing to ease of use, availability, and accessibility of insulin delivery devices.Some of the major primary and secondary sources included in the report for the diabetes care devices market are World Health Organization, American Diabetes Association, National Institute of Diabetes and Digestive and Kidney Diseases, Diabetes UK, Centers for Disease Control and Prevention, Chinese Diabetes Society, International Diabetes Federation and others.

Read the full report: https://www.reportlinker.com/p05774503/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-diabetes-care-devices-market-is-expected-to-reach-us-39-382-3-mn-in-2027-from-us-23-354-3-mn-in-2018--300990133.html

SOURCE Reportlinker

Follow this link:
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018 - Yahoo Finance

Danish company Novo Nordisk specializes in the diabetes market. The company appears to be making an entry into the Alzheimers market, which isnt as unusual or unexpected as it initially sounds.

It has been postulated for some time that Alzheimers disease is related to blood glucose levels and has been dubbed type 3 diabetes. Type 1 is an autoimmune disease, sometimes referred to as insulin-dependent diabetes. Type 2 is typically acquired and appears more related to insulin resistance and is related to obesity.

Back in 2017, Mayo Clinic participated in a multi-institution clinical trial evaluating an insulin nasal spray on Alzheimers patients.

This study has furthered our understanding of the gene that is the strongest genetic risk factor known for Alzheimers disease, said Guojun Bu, a Mayo neuroscientist, at the time. About 20% of the human population carriers this riskier form of [the gene] APOE, called E4.

About 50% of Alzheimers cases are associated to APOE4 according to the study, which was published in the journal Neuron. And people with type 2 diabetes have a higher risk of Alzheimers disease, although the reasons for it are not completely clear. In fact, type 2 diabetes almost doubles the risk of developing Alzheimers disease. One possible reason is reduced blood flow to the brain because of damage to blood vessels caused by diabetes.

Now, Novo Nordisk is involved in a clinical trial using the companys GLP-1 analogue diabetes drug Victoza to evaluate if the drug can improve brain function and cognition in Alzheimers patients. It is a Phase IIb clinical trial. In laboratory studies it has been shown to improve Alzheimers symptoms and decrease the amount of amyloid plaques in the brain, which are associated with the disease.

In an update on the trial site, it was noted that patients receiving the drug had a perceived change in their symptoms after they stopped taking it. As a result, at the end of the 12-month trial, all patients will be offered the opportunity to join a 12-month open-label extension trial.

Novo Nordisk shares recently popped, and Evaluate Pharma speculates that this was related to the companys participation in the trial after the Danish newspaper Brsen made the link. They also cited a recent note by analysts at Bernstein titled Is Alzheimers type 3 diabetes? suggesting a role for GLP-1 drugs.

Despite the evidence, not a lot of clinical trials have been conducted testing the hypothesis. Evaluate Pharma notes, Correlation does not equal causation, and a skeptical pharma sector has remained on the sidelines. Indeed, it is striking that the number of clinical trials testing the hypothesis can be counted on the fingers of one hand, and none has a corporate pharma company sponsor.

These include studies by the University of Aarhus, which published data in 2016, the third Military Medical University, whose trial was completed last year but has not published the data yet, the trial mentioned earlier with the Imperial College London and Victoza, one by the Universitaria di Parma, with results expected last year, and an ongoing trial by the National Institute on Aging due in December 2022.

The trial of Victoza by the Imperial College London will enroll 204 patients with mild Alzheimers dementia and is a double-blind, placebo-controlled design that will last 12 months. Its primary endpoint is measuring rates of glucose metabolism in the brain. Secondary endpoints will look at various measures of cognition, including Adas, CDR-sum of boxes and ADSC-ADL.

The University of Aarhus study demonstrated that six months of Victoza was linked to an increase in glucose metabolism compared to placebo but was not deemed statistically significant.

Continued here:
Is Alzheimer's Type 3 Diabetes? Novo Nordisk is Willing to Find Out - BioSpace

A new study by researchers from Boston University School of Public Health (BUSPH) and Chulalongkorn and Mahidol Universities in Bangkok, which was published in the journal PLOS ONE, found that the majority of Thai adults with diabetes were never diagnosed, but that most of those who were diagnosed did receive treatment and got the condition under control.

The study focused on the strengths and weaknesses of diabetes care in Thailand's universal health system, using the 2014 Thai National Health Examination survey (NHES V), the largest cross-sectional, noninstitutionalized population representative survey in Thailand, completed every five years.

TOPLINE DATA

Of the 15,663 Thai adults included in the study, 8.8% appeared to have diabetes based on their blood samples and/or reporting being treated for diabetes. Of those who appeared to have diabetes, the researchers found that 67.0% reported ever being screened for diabetes, 34.0% reported being diagnosed, 33.3% had been treated, and 26.0% had their diabetes under control.

KEY FINDINGS

There were several key findings from the report. The researchers identified significant unmet need for diabetes care in the Thai adult population, with 74% of those with diabetes having an unmet need for care across levels of screening, diagnosis, treatment, or control. Additionally, the high unmet need for diabetes care was found to be largely attributable to loss at the stages of screening and diagnosis, which each contributed 33% to total unmet need.

INISIGHTS & RECOMMENDATIONS

The study highlighted the need for stronger investment to strengthen primary health care in Thailand. An independent assessment after a decade of the Thai Universal Coverage Scheme (UCS) indicated that the focus on curative care may have contributed to lower resources for public health functions. While several national policies to improve diabetes screening and care have been passed, and a dedicated chronic care fund was established under UCS to strengthen screening and primary care for diabetes and hypertension in 2011, large gaps remain in disease detection.

Future steps might include expanding primary health care clinics and staff, in addition to auxiliary health providers like community pharmacists, who in prior studies have successfully managed diabetes and hypertension in conjunction with primary care providers.

Better health information systems that allow every Thai to access their personal health information, including diabetes risk and screening records, could also contribute to reducing unmet need.

ON THE RECORD

"Thai healthcare systems may have put emphasis on expanding coverage both in terms of population coverage and medical care benefit packages, which they did quite well with relatively low cost (and limited resources). Nevertheless, this paper highlights the importance of improving the quality of care, especially primary care and public health promotion and disease prevention," said study co-author Dr. Piya Hanvoravongchai, lecturer in the Department of Preventive and Social Medicine in the Faculty of Medicine at Chulalongkorn University in a statement.

See the rest here:
Researchers discover unmet needs in Thai diabetes care - Healthcare IT News

New cell treatment could help maintain healthy blood sugar levels

A new cell treatment to enhance islet transplantation could help maintain healthy blood sugar levels in Type 1 diabetes without the need for multiple transplants of insulin producing cells or regular insulin injections, research suggests.

In Type 1 diabetes the insulin-producing cells of the pancreas are destroyed. Insulin injections maintain health but blood glucose levels can be difficult to control. Currently in the UK it is estimated that approximately 400,000 people in the UK have type 1 diabetes.

The current recommendation for people with type 1 diabetes who have lost awareness of low blood glucose levels is the transplantation of islets the insulin producing part of the pancreas.

A study in mice found that transplanting a combination of islets with connective tissue cells found in umbilical cords known as stromal cells - could potentially reduce the number of pancreases required for the procedure.

Mice that received the islet-stromal cell combination were found to have better control of blood glucose and less evidence of rejection of islets after seven weeks, compared to those that received islets alone.

In humans, more than two donor pancreases, which are scarce, are often needed because islets can be rejected and are slow to form new blood supplies.

Therefore, multiple islet transplantations and anti-rejection medication are required to control blood sugar levels in people with Type 1 diabetes. Scientists at the University of Edinburgh hope their findings could be a way of overcoming these issues.

The researchers found that islets combined with stromal cells successfully returned normal blood glucose levels just three days after transplantation.

Other studies have used cells sourced from bone marrow and fat. This is the first to use stem cells from umbilical cords and has produced superior results.

The research is published in the journal Science Translational Medicine and funded by Chief Scientist Office in Scotland and Diabetes UK.

Shareen Forbes, Professor of Diabetic Medicine at the University of Edinburgh and Lead Physician for the Islet Transplant Program in Scotland, said: Should this research prove successful in humans, we could reduce the number of islets needed to control blood sugar levels using this co-transplantation approach. This would mean more people with Type 1 diabetes could be treated using islet transplantation while significantly reducing the waiting time on the transplant list.

John Campbell, Professor and Associate Director Tissues, Cells & Advanced Therapeutics at the Scottish National Blood Transfusion Service has said that further work is needed to establish the long-term safety of using this type of stromal cell in this setting before proceeding to clinical trials in humans.

Dr. Elizabeth Robertson, Director of Research at Diabetes UK, said: Islet transplants have been life changing for some people with Type 1 diabetes, treating dangerous hypo unawareness. But there currently arent enough donated pancreases to go around, and the procedure itself isnt yet as effective as it could be.

This new research from the University of Edinburgh is a promising step forward, and one we hope will lead to islet transplants becoming both more effective and more widely available in the future.

Register for your free SelectScience membership today to receive the latest editorial articles and technology news direct to your inbox>>

Excerpt from:
Cell therapy trialed in mice offers diabetes treatment hope - SelectScience

Tandem Diabetes (NASDAQ:TNDM)today announced the commercial launch of the newest version of its flagship insulin pump in the U.S. market. The company's signature t:slim X2 insulin pump will also now come with Control-IQ technology, which is meant to help stabilize blood sugar levels via an automated insulin dosing system.

Insulin pumps are a type of insulin delivery device that simulate the way the pancreas works by delivering small doses of insulin throughout the body. Tandem's main product is its t:slim X2 pump, one of the top insulin pumps in the market right now, with sales having seen dramatic growth over the past couple of years.

An insulin pump. Image source: Getty Images.

"Control-IQ technology has been described by study participants and investigators as 'life-changing,' 'easy to use,' and 'a new standard of care in insulin therapy management'," said Tandem CEO John Sheridan. This technology, which will be made available to existing t:slim users via a software update, is only compatible with one other insulin monitoring system out there,Dexcom's G6 continuous glucose monitoring tool (the G6, however, is not an insulin pump).

The Food and Drug Administrationapproved Tandem's Control-IQ platform back in December, and now that it's officially hitting the market, investors are excited to see how this will change Tandem's sales figures.

But there still are some serious biotech competitors that could pose a threat to Tandem's position in the market. The most notable isInsulet (NASDAQ:PODD), which is developing its own insulin pump, the Omnipod Horizon, that should be available sometime in late 2020. It's quite likely that Insulet's new pump will siphon off market share from Tandem.

The rest is here:
Tandem Diabetes Launches a New Version of Its Insulin Pump - The Motley Fool

A new study found a protein linked to Alzheimers Disease also contributes to problems with diabetes and obesity.

Its called the amyloid precursor protein or APP. Thats the same amyloid believed to form plaque that may cause cognitive decline. The study, published in Nature Metabolism, found APP occurs in far higher levels in the fat cells of mice and humans who are obese.

The studys senior author is Dr. Philipp Scherer of UT Southwestern Medical Centers Touchstone Center for Diabetes Research. Scherer talked with KERA about how APP causes problems in the bodys fat cells.

The KERA Interview with Dr. Philipp Scherer

INTERVIEW HIGHLIGHTS:

The Link Between APP And Diabetes

It turns out that high fat diets actually lead to the production of APP within the fat cell themselves. Then as the fat cell becomes challenged and less functional, we actually progress towards a type 2 diabetic state where we have high levels of insulin resistance.

The Diabetes Of The Brain

What's interesting is that we know from the Alzheimer's field that there is an association between type 2 diabetes and Alzheimer's disease. You sometimes hear Alzheimer's disease is the diabetes of the brain. This is based on the fact that the nerve cells become insulin resistant. We have high sugar levels in the brain that can actually enhance the formation of these plaques.

Even though we don't have plaque formation in our fat tissue, the very fact that the induction of APP can actually lead to this high level of dysfunction of our fat tissue is an interesting new spin, and we can certainly now also check in the brain whether or not a similar mechanism is associated with that neurodegeneration.

Perhaps Another Clue To What May Cause Alzheimers

We certainly have gained a lot of insights into what actually leads to the problems that we see in our fat tissue as we gain weight but I think we can also learn the lesson for the brain from this.

What we now see in the fat cells could actually also potentially apply to our nerve cells in the brain. They may actually engage in an energetic deficit, because within the nerve cells this APP protein may mislocalize and cause similar troubles that it causes in adipose (fat) tissue.

RESOURCES:

APP Study

UT Southwestern: Protein associated with Alzheimer's also causes dysfunction in fat cells, increasing obesity, diabetes risk

What Is Alzheimers Disease?

American Diabetes Association

Answers have been edited for clarity and brevity.

Visit link:
UTSW Study Links Alzheimer's-Related Protein To Diabetes And Obesity - KERA News

The American Diabetes Association (ADA) has made its annual changes to its Standards of Medical Care in Diabetes.

This year there is a strong recurring message of individualising patient care, including recommendations for treatment of cardiovascular disease, special considerations for older adults with type 1 diabetes, and revised recommendations and additional supporting evidence for use of rapidly changing diabetes technology.

The Standards are developed by the ADAs multidisciplinary Professional Practice Committee, made up of physicians, diabetes educators, and other expert diabetes healthcare professionals.

The guidelines are based upon the most current evidence-based recommendations for diagnosing and treating adults and children with all forms of diabetes.

Dr John Buse Ph.D., the Verne S. Caviness Distinguished Professor of Medicine, Division Chief of Endocrinology and Metabolism, and Director of the NC Translational and Clinical Sciences (TraCS) Institute, led the writing of the update, which includes:

To read the document in full, click here.

See the article here:
American Diabetes Association release updated Standards of Care - The Diabetes Times

Staff reports

MondayJan20,2020at1:12AM

HORNELL Informational sessions on the National Diabetes Prevention Program (NDPP) offered by the Steuben County Public Health department are set for February.

The two-year NDPP program helps participants lose weight, become more physically active, lower stress, and reduce their Type 2 diabetes risk. Participants must be at risk for developing Type 2 diabetes but not previously diagnosed with Type 1 diabetes.

Information on the program will be presented at:

Noon, Feb. 4 in the Steuben County Annex Room A, East Morris Street, Bath. Classes are set for noon-1 p.m. Tuesdays beginning Feb. 25.

5:45 p.m. Feb. 25 in the Hornell YMCA Art Room, 18 Center St., Hornell. Classes are set for 5:45- 6:45 p.m. Tuesdays beginning March 10.

Classes for the two-year program will be held weekly for four months; then meet biweekly and eventually meet every month.

The cost of the program is covered by Medicare, Medicaid and Steuben County employees participating in the countys Wellness program. Private pay for the program in $150.

To register, or for more information on the program, qualifying blood work or other questions, call (607) 664-2438, email lwagner@steubencountyny.gov, or register online.

For information on the Corning YMCAs Type 2 diabetes prevention program, call (585) 341-4064.

Read the original:
Steuben Diabetes prevention programs slated to begin soon - Hornell Evening Tribune

QYResearch Published GlobalRound Guide Rail SystemsMarket 2025 Report: Industry Growth, Opportunities, Vendors, Shares, Competitive Strategies And Forecasts

Los Angeles, United State, January 2020: This latest report provides a deep insight into theGlobal Round Guide Rail SystemsMarket 2019 covering all its essential aspects. Global Round Guide Rail Systems Market report provides pin-point analysis for changing competitive dynamics through comprehensive View of the key market dynamics. The research study provides market introduction, Round Guide Rail Systems market definition, regional market scope, sales and revenue by region, manufacturing cost analysis, Industrial Chain, market effect factors analysis, Round Guide Rail Systems market size forecast, 100+ market data, Tables, Pie Chart, Graphs and Figures, and many more for business intelligence.

The report then highlights factors affecting the development of market such as drivers, restraints, threats, and opportunities, technology advances, the latest market scenarios, etc.Key stakeholderscan consider statistics, tables & figures mentioned in this report for strategic planning which leads to the success of the organizations such as:

ThomsonRobert Bosch GmbHWickensNook IndustriesLOTEC Loh GmbHCo.KGVARIO Fertigungstechnik GmbHVenture GrindingWerkzeugmaschinenfabrik Glauchau GmbHErwin Junker Maschinenfabrik GmbHNUM AGBhrer AG

Get Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures):https://www.qyresearch.com/sample-form/form/1446405/Global-Round-Guide-Rail-Systems-Market

It monitors activity levels, quality of sleep, distance traveled, calories burned, and overall health and behavior 24/7.The global Round Guide Rail Systems market was xx million US$ in 2019 and is expected to xx million US$ by the end of 2025, growing at a CAGR of xx% between 2020 and 2025.

This report studies the Round Guide Rail Systems market size (value and volume) by player, region, product type and final industry, historical data 2014-2019 and forecast data 2020-2025; The report also explores global market competitive environment, market drivers and trends, opportunities and challenges, risks and barriers to entry, five forces analysis of sales channels, distributors and porters.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Round Guide Rail Systems in these regions, from 2014 to 2025, coveringNorth America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Turkey etc.)Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)South America (Brazil etc.)Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.

By the product type, the market is primarily split into Ball Guide SystemPin Roller Guide SystemContact Roller Guide SystemOther

By the end users/application, this report covers the following segments Machine ToolsIndustrial RobotsHeavy Machinery EquipmentGeneral MachineryAutomationCargo HandlingOther

The study objectives of this report are:To study and analyze the global Round Guide Rail Systems The report also explores global market competitive environment, market drivers and trends, opportunities and challenges, risks and barriers to entry, five forces analysis of sales channels, distributors and porters.To understand the structure of Round Guide Rail Systems market by identifying various subsegments.Share detailed information on key factors affecting market growth (growth potential, opportunities, drivers, industry challenges and risks).Focuses on the key global Round Guide Rail Systems manufacturers define, describe, and analyze sales volume, value, market share, market competitive environment, SWOT analysis, and development plans over the next few years.To analyze the Round Guide Rail Systems with respect to individual growth trends, future prospects, and their contribution to the total market.To project the value and volume of Round Guide Rail Systems submarkets, with respect to key regions (along with their respective key countries).

In this study, the years considered to estimate the market size of Round Guide Rail Systems are as follows:History Year: 2014-2019Base Year: 2018Estimated Year: 2020Forecast Year 2020 to 2025

This report includes the estimation of market size for value (million USD) and volume (K Units). Top-down and bottom-up approaches were used to estimate and verify market size of Round Guide Rail Systems market, to estimate the size of various other dependent submarkets in the overall market.

Available CustomizationsWith the given market data, QYResearch offers customizations according to the companys specific needs.Further breakdown of Round Guide Rail Systems market on basis of the key contributing countries.Detailed analysis and profiling of additional market players.

For Further Detailed insights and Any Query About Round Guide Rail Systems Market, Place your Query Here!- https://www.qyresearch.com/customize-request/form/1446405/Global-Round-Guide-Rail-Systems-Market

Table of Contents

ThomsonRobert Bosch GmbHWickensNook IndustriesLOTEC Loh GmbHCo.KGVARIO Fertigungstechnik GmbHVenture GrindingWerkzeugmaschinenfabrik Glauchau GmbHErwin Junker Maschinenfabrik GmbHNUM AGBhrer AG

About Us:

QY Research is committed and dedicated to assisting its clients in reaching towards their goals. We offer a comprehensive range of research reports and support our customers by providing them a solution across times zones. We understand the necessity of accurate data and therefore providing an in-depth analysis of the markets is our primary responsibility. The analytical mind of our expert team recognizes the need for the excellent quality control system, which validates data. This is why QY Research is one of the few consulting firms that gives importance to provide accurate and highly reliable data.

Read More Reports:

https://www.openpr.com/news/1904873/smart-access-control-system-acs-market-set-for-rapid-growth

https://www.openpr.com/news/1904870/pharmaceutical-processing-equipment-market-is-likely-to-show

Read more:
Diabetes Treatment Market 2019 Industry Growth, Competitive Analysis, Future Prospects And Forecast 2025 - Melanian News

A University of WisconsinMadison alumnus is now selling a patented device to help diabetics safely and easily inject insulin with just one hand. Once the Steady Shot device is mounted on a standard insulin injector, its two plastic wings compress the skin, raising a bulge of fat to receive the injection.

Fat is the target because when injected into muscle, insulin, the hormone that regulates blood sugar, can cause seizures if absorbed too quickly. Traditionally, the user forms the bulge with the thumb and one finger, while holding the injector with the other hand. The need to use two hands limits the area that can be injected.

With the ability to do a one-hand injection, suddenly diabetics can spread out the injections and preserve their skin. Photo courtesy of Steady Shot

Allowing one-handed injection has multiple benefits, says inventor Shawn Michels, a 2018 graduate of the Wisconsin School of Business and type I diabetic.

Normally, you need one hand to compress the skin, and the other to operate the insulin pen, which does the injection, he says. That means youre limited to the abdomen and thighs, but lifelong diabetics are injecting several times a day, which causes scarring and lipohypertrophy, a buildup of fat globules after repeated injections.

These globules are not only unsightly, but because they cause uneven insulin absorption, these structures impair consistent control of blood sugar.

Now that he can inject in the back, buttocks and back of the legs, even the arm, his available injecting area is almost doubled, Michels says.

Michels invention received a utility patent last month. As an over-the-counter device, it needs no FDA clearance.

The injection innovations on the market all have moving parts and much greater complexity, compared to Michels one-piece attachment.

Shawn Michels, 24, invented a new insulin-injection device in 2016 while earning a B.A. in business at University of WisconsinMadison. Steady Shot is now on the market. Photo courtesy of Shawn Michels

Michels began germinating the idea while in business school at UWMadison. Back when I was an undergraduate, I was thinking about how to inject you may have to do it while driving, or in an airplane, and its always awkward when reaching certain injection sites, Michels says. I saw these other devices, and had the Aha! moment when I realized that if you press these two wings against the skin, a bulge of skin and fat would rise up. That realization led me to a much simpler design without moving parts.

The wings have other benefits, Michels says. First off, they tend to hide the needle, reducing the fear response that needles often initiate.

Second, when the device presses against the skin, the user initially feels the wings, which make a much bigger impression than the needle. When they feel the arms on the skin, they will not feel the needle going in, Michels says.

Thats particularly helpful for young people with a new diagnosis, Michels says. They are often scared of the needle, but Steady Shot obscures the sight of the needle, without impairing the injection.

Third, moving the injections around the body is better for the skin, and easier on the user, he says. We do this multiple times a day, and that can produce fat globules and scarring. Any way we can spread the injection around should give the skin a rest and reduce these side effects while allowing us to receive our lifesaving medicine.

Unlike some injection innovations, Steady Shot relies on no moving parts. The wings bunch up the skin to ensure that insulin is injected into fat, not muscle. Photo courtesy of Steady Shot

Michels benefited from several business plan competitions while at UWMadison. What helped most, however, was Discovery to Product, or D2P, a program to help university students, faculty and staff evaluate promising ideas and usher them toward the market.

D2P funding supported creation of the Steady Shot mold, and the group provided contacts at professional networks. They connected me with UW Health, which helped me understand the lay of the land in the hospital. I thought initially this could be used inpatient in the hospital for all sorts of injections, but they convinced me it would be best for outpatients, for self-injectors.

D2P also provided a link to business mentors, Michels added. They helped me select the best part of market to tackle first, and talked about the lean startup model. When I started, I was completely in the dark. I did not know anything about entrepreneurship; I was starting at ground level.

On Monday, Michels launched a crowd-funding campaign at Indiegogo. The most surprising part of the journey was how long things take, he says. You think, I have this really simple device, its plastic, one piece. You think you could get market instantly but that hasnt been the case. But now is the time. Were really happy with the reviews and testimonials were getting. This simple device solves real problems.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Go here to read the rest:
Diabetic's invention is an injection innovation - University of Wisconsin-Madison

Diabetes Professional Care Charity of the year, X-PERT Health, has appointed digital healthcare agency, Pulse, to transform their ground-breaking diabetes education programme onto a digital platform.

The new platform, which will be accessible via an app or website, will enable X-PERT Health to scale up its current group based programme, allowing hundreds of thousands more patientsto develop the knowledge, understanding and confidence to make lifestyle changes to prevent or manage Type 2 diabetes, further strengthening X-PERT Healths educate not medicate philosophy.

Recommended AI News: Accenture Announces Changes to Its Growth Model and Global Management Committee

The educational content will be interactive and engaging, including animated videos, games and quizzes to support discovery learning in a fun and easy-to-use way. The digital programme will also include features such as real-time tracking for diet, physical activity, health results, medication requirement and mood and sleep helping users to manage and improve their lifestyle and health. This information can then be shared with the users healthcare professional as part of their regular check-up.

Users will also have continued support from a 24/7 chatbot; group chats; access to the X-PERT health forum, and the ability to book a call with an X-PERT Health coach. In addition, users will be able to access a large database of recipes, tailored for patients with Type 2 diabetes, and they will also be able to submit their own recipeswhich can be shared with other patients.

Recommended AI News: BlockchainArmy Plans to Manage Space Debris Through Blockchain; Launches SOS Program

X-PERT Health Founder, DrTrudi Deakin, said:

The X-PERT Programmes have reached and benefitted over 300,000 patients through collaborations with the NHS, for over a decade. We selected Pulse to help us seizethe opportunity in this digital age to overcome accessibility barriers to structured education by releasing a truly innovative means of delivering our evidence based programme at scale: X-PERT Health Diabetes Digital. This programme encompasses behaviour change philosophies, lifestyle change and state-of-the-art integrations and functionalities to meet the needs of the patients and improve overall health and wellbeing.

Pulse Chief Digital Officer,Leo Miller, added:

Were delighted to have been chosen to take X-PERT Healths diabetes education programme into the digital space, and we are very much looking forward to working together with the X-PERT Health team to support patients in preventing or managing Type 2 diabetes.

Recommended AI News: Domo Ranked No. 1 in Dresner 2019 Big Data Analytics Market Study

View original post here:
Leading Digital Healthcare Agency, Pulse, Selected to Innovate Award-Winning Diabetes Education Programme - AiThority